Ostensibly, these data were the principal motivation behind the GLACIER study, which aimed to test whether Gedatolisib, in combination with the anti‐malaria drug hydroxychloroquine, showed any evidence of DTC eradication in patients with TNBC or with HER2‐amplified breast cancer. This evidence concerns the gene ERBB2 and breast cancer.